Alcon Inc. (NYSE: ALC) saw its stock price soar 5.14% in after-hours trading on Tuesday following the release of its third-quarter 2025 earnings report, which exceeded analyst expectations on the bottom line. The eye care giant reported quarterly adjusted earnings of $0.79 per share, outperforming the consensus estimate of $0.76 by 3.95%.

While Alcon's Q3 revenue of $2.589 billion fell slightly short of the $2.603 billion analyst estimate, it still represented a solid 6.41% increase from the same period last year. The company's performance was particularly strong in its equipment segment, with sales jumping 13% to $243 million. This growth was primarily driven by recent product launches, including the Unity VCS system.

Investors were also encouraged by Alcon's performance in the Vision Care segment, which grew 7% to $1.169 billion. The company's ocular health division showed strong momentum, with sales increasing 7% to $462 million, led by products for dry eye and glaucoma, such as Systane, Tryptyr, and Rocklatan.

Despite facing some competitive pressures, Alcon maintained its full-year 2025 guidance, projecting net sales between $10.3 billion and $10.4 billion, and core diluted earnings per share in the range of $3.05 to $3.15. This reaffirmation of the company's outlook likely contributed to investor confidence, driving the stock's after-hours rally.